Loading clinical trials...
Loading clinical trials...
A First-in-Human, Randomized, Double-Blind, Placebo/Active Controlled, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics Following Subcutaneous Injections of YH35324 in Atopic Healthy Subjects or Subjects with Mild Allergic Diseases
Conditions
Interventions
YH35324
Placebo
+1 more
Locations
4
South Korea
Ajou University Hospital
Suwon, Gyeonggi-do, South Korea
Asan Medical Center
Pungnap-tong, Seoul, South Korea
Severance Hospital, Yonsei University Health System
Sinchon-dong, Seoul, South Korea
Seoul National University Bundang Hospital
Gumi, Sungnamsi, South Korea
Start Date
September 26, 2021
Primary Completion Date
January 25, 2023
Completion Date
January 25, 2023
Last Updated
December 3, 2024
Lead Sponsor
Yuhan Corporation
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions